The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 8:19 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #11. Actavis Four Products from Akorn

Acquirer: Actavis (NASDAQ:ACT)
Acquiree: Four Products from Akorn
Details: Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed.

Enact Holdings is a private mortgage insurance company. Through its subsidiaries, Co. provides credit protection to mortgage lenders and investors, covering a portion of the unpaid principal balance of mortgage loans where the loan amount exceeds 80% of the value of the home ("low-down payment loans"). Co.'s credit protection provides families access to homeownership sooner than would otherwise be possible. Co. facilitates the sale of mortgages to the secondary market, including to the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation and private investors, and protect the balance sheets of mortgage lenders that retain mortgages in their portfolios.

ACT SEC Filing Email Alerts Service

Preferred: ACT.PRA

Open the ACT Page at The Online Investor »

Company Name: 
Enact Holdings Inc
Stock buyback: 
ACT buyback
Insurance Brokers
Number of ETFs Holding ACT: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the ACT Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree ACT Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.50 out of 4)
2nd percentile
(ranked lower than approx. 98% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 11 of 100 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.